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Background: The advent of IMRT and image-guided radiotherapy (IGRT) in combination with involved-field
radiotherapy (IF-RT) in inoperable non-small-cell lung cancer results in a decreased incidental dose deposition in
elective nodal stations. While incidental nodal irradiation is considered a relevant by-product of 3D-CRT to control
microscopic disease this planning study analyzed the impact of IMRT on dosimetric parameters and tumor control
probabilities (TCP) in elective nodal stations in direct comparison with 3D-CRT.
Methods and materials: The retrospective planning study was performed on 41 patients with NSCLC (stages II-III).
The CTV was defined as the primary tumor (GTV + 3 mm) and all FDG-PET-positive lymph node stations. As to
the PTV (CTV + 7 mm), both an IMRT plan and a 3D-CRT plan were established. Plans were escalated until the
pre-defined dose-constraints of normal tissues (spinal cord, lung, esophagus and heart) were reached. Additionally,
IMRT plans were normalized to the total dose of the corresponding 3D-CRT. For two groups of out-of-field
mediastinal node stations (all lymph node stations not included in the CTV (LNall_el) and those directly adjacent to
the CTV (LNadj_el)) the equivalent uniform dose (EUD) and the TCP (for microscopic disease a D50 of 36.5 Gy was
assumed) for the treatment with IMRT vs 3D-CRT were calculated.
Results: In comparison, a significantly higher total dose for the PTV could be achieved with the IMRT planning
as opposed to conventional 3D-CRT planning (74.3 Gy vs 70.1 Gy; p = 0.03). In identical total reference doses, the
EUD of LNadj_el is significantly lower with IMRT than with 3D-CRT (40.4 Gy vs. 44.2 Gy. P = 0.05) and a significant
reduction of TCP with IMRT vs 3D-CRT was demonstrated for LNall_el and LNadj_el (12.6 % vs. 14.8 %; and 23.6 % vs
27.3 %, respectively).
Conclusions: In comparison with 3D-CRT, IMRT comes along with a decreased EUD in out-of-field lymph node
stations. This translates into a statistically significant decrease in TCP-values. Yet, the combination of IF-RT and IMRT
leads to a significantly better sparing of normal tissues and higher total doses whereas the potential therapeutic
drawback of decreased incidental irradiation of elective lymph nodes is moderate.* Correspondence: jochen.fleckenstein@uks.eu
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Radiochemotherapy is the standard treatment for inop-
erable, non-metastasized non-small-cell lung cancer
(NSCLC). Radiotherapy planning of NSCLC underwent
major changes during the past decade. Both the integra-
tion of FDG-positron emission tomography (FDG-PET)
and the shift to involved-field radiotherapy (IF-RT) be-
came a new therapeutic standard [1]. It was shown in a
series of trials that IF-RT (in the context of FDG-PET
based treatment planning) does not go along with an
unacceptable risk of isolated failure in ‘out-of-field’ lymph
node stations but allows for further dose escalation [2–6].
The favorable low rates of ‘out-of-field’-failure with IF-RT
were also attributed to a significant dose-deposition in
elective nodal areas with the use of 3D-conformal radio-
therapy (3D-CRT) [7, 8]. Meanwhile, a transition from
3D-CRT to intensity modulated radiotherapy (IMRT) in
NSCLC takes place [9, 10]. Given the fact that IMRT is of
additional benefit with respect to dose escalation and the
sparing of relevant organs at risk (OAR) [11–13], it is yet
unclear if the high dose conformality of IMRT implies an
adverse effect on tumor control probability (TCP) for
microscopic disease in the “rind”-region outside the clin-
ical target volume. This therapeutic backdrop was the
incentive to perform the presented in silico-analysis,
which is a head-to-head comparison of IMRT and 3D-
CRT in terms of dose distribution and hypothetical TCP
in out-of-field mediastinal and hilar lymph node stations.
It was carried out on a group of 41 patients who had
participated in the ‘PET-PLAN pilot trial’, which examined
the rate of isolated ‘out-of-field’ nodal failures with FDG-
PET based IF-RT [6].
Methods
Patient selection and planning conditions
Forty-one patients who had been enrolled in the previ-
ously published ‘PET-PLAN pilot trial’ were selected for
the presented in silico analysis [6]. It was approved by the
local ethics committee (Ärztekammer des Saarlandes),
and all participating patients had given written informed
consent. All selected patients had pathologically con-
firmed, medically inoperable stage II-III NSCLC and were
candidates for definitive radio(chemo)therapy. Further
inclusion criteria and the detailed modality of both the
computed tomography and 18F-FDG-PET acquisition as
prerequisites for the treatment planning are described in
the preceding publication [6].
Target volumes and treatment planning (IMRT and 3D-CRT)
FDG-PET-based target volumes were defined by a radi-
ation oncologist with the support of a radiation physicist
and a nuclear medicine physician. The registration of CT
and FDG-PET-image sets was scrutinized for anatomical
plausibility and – if necessary - manually adjusted. Thegross tumor volume (GTV) of the primary tumor was
initially autocontoured with a contrast-oriented source-to-
background (‘S/B’) algorithm for FDG-PET–based delin-
eation of tumor volumes as described by Nestle et al. [14]
and subsequently adjusted to the tumor borders as shown
in the CT scan displayed in soft tissue and lung window.
FDG-PET–negative atelectasis was excluded from the
GTV. The GTV was expanded to the clinical target vol-
ume (CTV) by 3 mm in all dimensions; then, the CTV
was expanded by another 7 mm to create the planning
target volume (PTV) for the primary tumor.
As to the involved lymph nodes, only American Joint
Committee of Cancer (AJCC)-lymph node stations con-
taining FDG-PET-positive lymph nodes were contoured
as CTV, referring to an anatomical contouring guide [15],
whereas CT-positive but FDG-PET-negative lymph nodes
were disregarded. The nodal CTV was then expanded by
7 mm to obtain the PTV for the involved lymph node
stations. Finally, the definitive PTV was obtained from the
unification of the PTVs of the primary tumor and the
involved lymph node stations.
Dose constraints for normal tissues were defined as
follows: for the whole lung (the GTV of primary tumor
had been subtracted from the contoured lung volume)
V20 ≤ 35 %, and mean lung dose (MLD) ≤ 20 Gy; the
spinal cord 45 Gy as maximum; the esophagus V50 ≤ 50 %
or mean dose ≤34 Gy and maximum dose ≤70 Gy; and
the heart V45 ≤ 67 % and V60 ≤ 33 %.
For each patient, both an IMRT- and a 3D-CRT-
treatment plan were generated and optimized by an
experienced radiation physicist, using the PINNACLE3
treatment planning system (Version 8.2, Philips Medical
Systems, Best, The Netherlands). IMRT “step-and shoot”
plans (photon energy: 6 MV) were calculated using ‘dir-
ect machine parameter optimization’. The final dose dis-
tribution was calculated with a collapsed cone algorithm.
Typically, six or seven coplanar beams with 70 segments
were used; the beam angles were individually adapted.
Inverse planning was started with a default prescription
dose of 70 Gy and standardized objectives for the cover-
age of the planning target volume (PTV) as provided by
the ICRU Report 83 were applied [16]. To allow for
potential dose escalation, pre-defined lower OAR con-
straints were used as default values for the initial 70 Gy
plan: whole lung – V20 < 28 %; heart – V40 < 20 %; spinal
cord – maximum dose of 40 Gy; esophagus – V50 < 50 %
and maximum dose of 70 Gy. The total prescription dose
was escalated or deescalated by 2 Gy starting with 70 Gy
until all dosimetric premises with respect to PTV coverage
and OARs were met. To compare IMRT with 3D-CRT
plans at equal dose levels with respect to dose distribution
in out-of-field lymph node stations and sparing of OARs,
IMRT plans were additionaly normalized to the same
maximum dose level (defined as total reference dose, Dref )
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labeled as IMRTnorm). The normalization was achieved by
matching the number of fractions of the IMRT plans with
those of the 3D-CRT plans (no de novo IMRT-planning
was performed for dose normalization).
For 3D-CRT planning at least three beams had to be
used and the number and arrangement of beams and their
weights, the use of wedges as well as the photon energy (6
and 18 MV) were optimized by an experienced medical
physicist.
A minimal total prescription dose of 60 Gy was aspired
and depended on the dose constraints for normal tissues.
The prescribed single dose was 2 Gy and the total pre-
scription dose was incrementally escalated by 2 Gy as long
as the dose constraints outlined above were not surpassed.
The maximum doses for both the IMRT and the 3D-CRT
plan were limited to 110 Gy.
Contouring and grouping of out-of-field lymph node
stations
All hilar and mediastinal AJCC-lymph node stations were
contoured based on the individual CT-anatomy according
to the atlas provided by Chapet et al. [15]. Specifically, two
nodal ‘out-of-field’-volumes were defined for each patient.
The first volume, LNall_el, comprised the entire elective
hilar and mediastinal lymph node stations, i.e. all unin-
volved levels outside the CTV. The second volume, LNad-
j_el, included only the elective ‘out-of-field’-lymph node
levels 7 (infracarinal, if uninvolved), the ipsilateral hilum
(levels 10/11, if uninvolved) and those uninvolved and dir-
ectly adjacent to (involved) lymph node levels included in
the CTV. For example, if only level 4R (deep paratracheal
lymph nodes, right side) was involved, the volume Lnadj_el
contained the bordering lymph node levels 2R, 4 L, 7 and
10_11R.
Dose distribution in out-of-field nodal regions
Dose volume histograms (DVH) were created for both
delineated out-of-field lymph node volumes (LNall_el,
LNadj_el) for three plans in each patient (3D-CRT, IMRT
and IMRTnorm). For LNall_el and LNadj_el mean doses were
calculated and additionally (in order to correct for hetero-
geneity in dose distribution), the equivalent uniform dose
(EUD) was derived from DVH-based values by using the









where N is the number of voxels in the anatomic region
of interest, Di the dose in the i th voxel, and a is a
tumor-dependent value, which describes the dose-vol-
ume effect. The EUD-concept was designed to translate
a heterogeneous dose distribution in a given volume intoan isoeffective (hypothetical) homogeneous dose distri-
bution with the compared biologic effect mostly being
tumor control. One advantage of the EUD-concept is
that it simplifies the comparison of volumes with various
heterogeneous dose-distribution while it remains at the
same time an objective measure.
Tumor control probability
TCP values were computed for LNall_el and LNadj_el in
all three plan variants (3D-CRT, IMRT and IMRTnorm).





where D50 is the dose needed to obtain a 50 % TCP, D is
the actual total dose deposited in the irradiated volume,
and γ is the normalized slope of the sigmoidal response
curve at D50. Parameters to control microscopic disease
in lung cancer were used as provided by Okunieff et al.
[19]. Precisely, D was derived from the computed EUD,
D50 was 36.5 Gy and γ was 0.72.
Statistical analysis
The paired sample t-test was used to test for statistical
differences between data sets in case of normal distri-
bution, otherwise the Wilcoxon signed rank test was
applied. Differences were considered significant when the
p-value was <0.05. Origin Pro 9.0 (OriginLab Corpor-




The patient characteristics are presented in Table 1. Pri-
mary tumors were located as follows: centrally (left: n =
10; right: n = 16), left upper lobe (n = 6), left lower lobe
(n = 3), right upper lobe (n = 3) and right lower lobe (n =
3). Thirty-nine patients had lymph node involvment as
diagnosed with FDG-PET. Six patients had a ‘single level’
involvement and 33 patients had a ‘multilevel’ spread.
The mean number of involved lymph node stations was
2.5 ± 0.9 sd (standard deviation).
Comparison of IMRT and 3D-CRT planning
Relevant PTV-based planning parameters are shown in
Table 2. With IMRT-planning a significangly higher mean
total dose could be achieved as compared with 3D-CRT
(74.3 vs. 70.1 Gy, p < 0.00001). Also, 7 of 41 patients could
be administered a total dose of 66 Gy or more with IMRT.
These results can be ascribed to the superior dose con-
formality of IMRT vs. 3D-CRT (CI: 0.79 vs. 0.50, p <
0.00001) resulting in an improved sparing of OAR, which
Table 1 Patient characteristics
Total no. of patients 41
Age, years

























Mean ± SD 63 ± 15
SD standard deviation, KPS Karnofsky Performance Score, FEV1 Forced
expiratory volume during 1st second of breathing maneuver
aAs staged with FDG-PET
Table 2 IMRT vs. 3D-CRT: PTV based dosimetric parameters of
all 41 patients
IMRT 3D-CRT p
PTV, cm3 433.3 ± 168.8
Total dose (Dref)
Median (range), Gy 72 (62–110) 70 (58–100)
Mean ± SD, Gy 74.3 ± 9.1 70.1 ± 7.9 <0.00001
≥60 Gy, no. (%) 41 (100) 40 (98)
≥66 Gy, no. (%) 39 (95) 32 (78)
Dmean-PTV, Gy ± SD 73.6 ± 9.0 70.0 ± 8.1 <0.00001
D90-PTV, Gy ± SD 71.3 ± 9.0 66.9 ± 7.8 <0.00001
CI ± SD 0.79 ± 0.04 0.50 ± 0.10 <0.00001
IMRT intensity modulated radiotherapy, 3D-CRT 3D-conformal radiotherapy,
PTV planning target volume, Dref prescribed reference dose, SD standard
deviation, Dmean mean dose in predefined region of interest, D90 dose,
administered to 90 % of region of interest, CI conformal index
Table 3 IMRT vs. 3D-CRT: dosimetric parameters for relevant
organs at risk of all 41 patients. IMRT dose was also normalized
to a prescription dose equaling 3D-CRT dose in each patient,
indicated as IMRTnorm
IMRT IMRTnorm 3D-CRT p
Lung
mean dose, Gy 17.3 ± 2.7 16.7 ± 2.7 17.2 ± 3.0
V20, % 28.3 ± 4.9 27.2 ± 7.3 28.4 ± 5.3
Esophagus
mean dose, Gy 26.8 ± 9.0 25.3 ± 9.3 26.0 ± 10.0
V60, % 14.8 ± 12.8 11.1 ± 12.2 17.1 ± 14.4 <0.0001*
V50, % 25.7 ± 18.1 23.0 ± 17.4 29.1 ± 18.5
Dmax, Gy 65.7 ± 8.6 59.6 ± 13.9 63.6 ± 12.0 <0.05*
Spinal cord
Dmax, Gy 38.8 ± 6.9 36.3 ± 7.4 39.5 ± 9.7 <0.01*
Heart
V60, % 2.1 ± 2.6 1.5 ± 1.9 4.6 ± 5.8 <0.01*
V45, % 6.7 ± 8.6 4.8 ± 5.9 10.4 ± 11.3 <0.01*
Data are presented as means ± standard deviation
IMRT intensity modulated radiotherapy, 3D-CRT 3D-conformal radiotherapy,
Dmax maximum point dose within the defined organ at risk, V20, V10 …
percentage of volume of the defined organ at risk receiving more than the
indicated dose
*Test for statistical significance performed for IMRTnorm vs. 3D-CRT (values only
indicated if significant)
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superior to 3D-CRT in sparing the spinal cord (Dmax)
and limiting the exposure of the esophagus with higher
doses (V60). Differences between IMRT and 3D-CRT in
regard to PTV coverage and OAR-exposure are exempli-
fied in one patient in Fig. 1a.
Dose distribution and TCP in out-of-field lymph node
stations
Values referring to mean dose, EUD, and TCP in LNall_el
and LNadj_el are presented in Table 4. If regarded at nor-
malized dose levels (IMRTnorm vs. 3D-CRT), mean dose
in LNall_el and LNadj_el was significantly decreased with
IMRTnorm. EUD was significantly decreased with IMRT
and IMRTnorm in comparison with 3D-CRT. The sig-
nificantly lower doses in LNall_el and LNadj_el with
IMRTnorm vs. 3D-CRT translated into significantly, butoverall moderately reduced values in TCP. TCP-values
did not differ significantly between IMRT and 3D-CRT if
IMRT is used for additional dose-escalation.
In Fig. 1b the delineated out-of-field lymph node sta-
tions and the resulting DVH for both volumes LNall_el
and LNadj_el are depicted for one patient.
Discussion
The presented planning study revealed a potential hazard













































































Fig. 1 Comparison of 3D-CRT vs. IMRT-treatment planning, shown for one patient with stage IIIA NSCLC in the left hilum. a IF-RT planning with
treatment volume: FDG-PET based PTV (red, colorwash). With IMRT planning (second row) administration of a total dose of 78 Gy would be
possible vs. 72 Gy with 3D-CRT (first row). Mean lung dose was dose limiting both in 3D-CRT and IMRT (see dose-volume-histogram (DVH)).
b Example for atlas-based individual delineation of single thoracic lymph node stations (first row) according to Chapet et al. [15]. Out-of-field
lymph node stations were subsequently merged to two regions of interest: first, LNall_el, i.e. all out-of-field lymph nodes stations (green, colorwash),
and second, LNadj_el, i.e. uninvolved lymph node stations 7 and 10/11 (ipsilateral) or anatomically adjacent to involved lymph node stations (pink
line). The DVH reveals a lower dose exposition for both sets of out-of-field lymph node stations for two IMRT-plans (with or without additional
dose escalation (IMRT and IMRTnorm, respectively) as opposed to 3D-CRT
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of-field lymph node stations and may thus involve the risk
of an increased rate of out-of-field nodal failure. However,
this holds true only under the condition that 3D-CRT and
IMRT are compared at equalized dose levels. Furthermore,
the calculated differences in TCP were slim between
IMRTnorm and 3D-CRT (12.6 % vs. 14.8 %). As our results
show: if the full potential of IMRT for dose escalation were
exploited, no signficant difference would be observed in
TCP-values compared to 3D-CRT, while EUD in out-of-
field lymph node stations still remained lower. These find-
ings indicate that one cannot count as much on IMRT as
on 3D-CRT to compensate for inaccurate nodal staging by
providing effective incidental dose-coverage in electivenodal regions. It is of note that only an increased rate of
isolated nodal failure (as opposed to a combined in-field
and out-of-field recurrence) should be considered as detri-
mental for IMRT. However, some meaningful strengths of
IMRT in combination with IF-RT have to be weighed
against its potential adverse effects on tumor control in
elective nodal regions. As we could demonstrate, IMRT
opens the door to a significant dose-escalation or alterna-
tively embodies the benefit of substantial sparing of
normal tissues at an equal total dose to that of 3D-CRT.
To our knowledge this is the first study examining the
dose distribution in elective lymph node stations adja-
cent to the CTV in the context of IF-IMRT in NSCLC.
Several planning studies examined the potential benefits
Table 4 IMRT vs. 3D-CRT: PTV based dosimetric parameters
stratified by treatment volume concept for all 41 patients. IMRT
dose was also normalized to a prescription dose equaling
3D-CRT dose in each patient, indicated as IMRTnorm
IMRT IMRTnorm 3D-CRT p
Mean dose (Gy)
LNall 36.7 ± 11.0 32.5 ± 7.5 37.1 ± 9.9 <0.0001*
LNadj 46.6 ± 9.7 37.9 ± 9.3 47.6 ± 8.6 <0.0001*
EUD (Gy)
LNall 32.2 ± 8.7 30.5 ± 8.3 33.5 ± 9.7 <0.01**/<0.00001*
LNadj 42.7 ± 9.3 40.4 ± 8.7 44.2 ± 9.0 <0.001**/<0.00001*
TCP (%)
LNall 13.8 ± 11.2 12.6 ± 9.9 14.8 ± 13.2 <0.01*
LNadj 25.7 ± 21.4 23.6 ± 19.4 27.3 ± 21.7 <0.001*
Data are presented as means ± standard deviation
IMRT intensity modulated radiotherapy, 3D-CRT 3D-conformal radiotherapy,
PTV planning target volume, LNall all hilar and mediastinal lymph node
stations without evidence of disease as staged with FDG-PET, LNadj hilar and
mediastinal lymph node stations without evidence of disease as staged with
FDG-PET, but directly adjacent to involved lymph node stations, TCP tumor
control probability, ns not significant
*Test for statistical significance performed for IMRTnorm vs. 3D-CRT (values only
indicated if significant)
**Test for statistical significance performed for IMRT vs. 3D-CRT (values only
indicated if significant)
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regions when using 3D-CRT [7, 8, 20, 21]. Even with
PET-based IF-RT of stage III NSCLC, rates of out-of-
field nodal recurrences can be as high as 10 % and there-
fore cannot be considered as insignificant [22]. It is con-
troversial if these recurrences can be attributed either to
the small a priori risk of microscopic involvement in
elective nodal regions or the benefits of incidental nodal
irradiation. Yet, thorough dosimetric analyses of isolated
out-of-field nodal failures indicate a dose–response rela-
tionship, and a critical cutoff may be in the range of 40–
50 Gy [7, 21]. Depending on the total burden of subclin-
ical disease a wide range of therapeutic total doses can
be assumed [23]. For a collective of patients with node-
negative head and neck cancer a reduction of neck
relapses by more than 90 % with total doses of 50 Gy
and by less than 50 % with less than 30 Gy (2 Gy single
fraction) was reported [24]. In that context it has to be
stressed that the calculation of the presented TCP values
is inaccurate inasmuch as neither the ‘true’ load of
subclinical disease nor the ‘true’ tumoricidal doses re-
main known for the average patient. Nevertheless, the
use of somewhat arbitrary radiobiologic parameters for
TCP-estimation still provides some guidance when
comparing individual dose disbributions. Also, the TCP-
values should be regarded as complementary to the by
far more objective EUD-concept.
As the use of IMRT has been widely adopted for inoper-
able stage III NSCLC our results underline the importanceof keeping track of out-of-field recurrences at times when
highly conformal dose distributions and tight margins
around the CTV are applied in the era of image-guided
radiotherapy.
Conclusions
Incidental irradiation of out-of-field lymph node stations
in NSCLC may be beneficial with respect to control of
microscopic lymph node involvement. With IMRT,
smaller doses are deposited in lymph node stations adja-
cent to the CTV due to its higher conformality as com-
pared to 3D-conformal radiotherapy. The planning study
presented here shows a moderate yet statistically signifi-
cant reduction in hypothetical tumor control probability
for microscopic involvement in out-of-field lymph node
stations for IMRT vs. 3D-CRT at equal dose levels. This
potential drawback may be outweighed by the superior-
ity of IMRT in sparing organs at risk and by its potential
to achieve higher total doses in the GTV. Yet, accurate –
i.e. FDG-PET based – lymph node staging seems to be an
important prerequisite for IMRT.
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